Bea Lavery

Vice President, Regulatory Affairs at Genentech/Roche | San Francisco, California, United States

About Bea Lavery

Bea Lavery is a dynamic leader in the field of regulatory affairs, currently serving as the Regulatory Portfolio Strategy Lead at Genentech/Roche since June 2023. With a robust background in oncology, she has spent the previous six years as the Global Regulatory Oncology Therapeutic Area Head, where she spearheaded numerous pivotal projects that advanced the development and approval of innovative therapies. Her expertise in navigating complex regulatory landscapes has been instrumental in bringing cutting-edge treatments to patients, particularly in the realm of immunology and oncology.

Bea's passion for translating science into actionable strategies is evident in her approach to regulatory portfolio management. She leverages her deep understanding of the scientific method and clinical trials to inform regulatory submissions and ensure compliance with Good Clinical Practice (GCP) standards. Her ability to synthesize data from diverse life experiences allows her to see every challenge as an opportunity for growth, both personally and professionally.

In her current role, Bea is focused on aligning regulatory strategies with the broader goals of drug development, ensuring that Genentech/Roche remains at the forefront of innovation in the life sciences sector. Her leadership skills are complemented by her proficiency in German, which enhances her ability to collaborate with international teams and navigate global regulatory requirements. Bea’s commitment to mentoring others and fostering a culture of inclusivity reflects her belief that diverse perspectives drive better outcomes in healthcare. Through her work, she continues to illuminate pathways for others, helping them find their light in the complex world of biotechnology and regulatory affairs.

Bea Lavery Work